Accent MicrocellShare price, financial results, shareholding and management
- Market cap
- ₹1,466 cr
- Stock P/E
- 33.4peers 21.3
- Book value
- ₹115
- Price to book
- 5.32
- EV / operating profit
- 25.5
- Market cap to sales
- 4.20
- ROCE · FY26
- 24.9%
- ROE · FY26
- 18.7%
- ROE, 3-year average
- 21.7%
- Operating margin · FY26
- 16.2%peers 8.9%
- Sales growth, 3 years
- 21.0%
- Profit growth, 3 years
- 54.0%
- Debt to equity
- 0.00peers 0.48
- Borrowings
- ₹0.9 cr
- Interest cover
- 108.9×
- Cash from business / op. profit
- 33%
- Debtor days
- 95
- Pledged
- 0.00%
- Promoter holding
- 53.02%
- Change in promoter holding
- -2.45 pts
- Shareholders
- 3,178
- 52-week high / low
- ₹732 / ₹280
- Dividend yield
- Paid
- Face value
- ₹10
Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.
Accent Microcell share price chart
Close on 6 Nov 2026 · -2.57% on the day · Vol 12,500
Daily prices to 6 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.
Share price returns
To the close of 6 Nov 2026
- 1 month
- -8.3%
- 3 months
- +12.3%
- 6 months
- +30.0%
- 1 year
- +117.7%
- Traded a day, 20 days
- ₹3.29 cr
- Taken for delivery
- 71%
Business growth
Sales and net profit, from the reported results
| Sales | Profit | |
|---|---|---|
| FY26 on FY25 | +32% | +33% |
| 3 years, a year | +21% | +54% |
| Latest half, H2 FY26 | +51% | +55% |
About Accent Microcell: business, products and customers
Accent Microcell makes plant based powders from wood pulp that drug, supplement and food makers use to bind and fill tablets and other products. Most of what it makes goes abroad, and its shares trade on NSE Emerge.
Accent Microcell makes microcrystalline cellulose (MCC), a purified powder made from wood pulp that holds tablets together, along with related excipients: silicified MCC, MCC spheres, powdered cellulose, croscarmellose sodium and magnesium stearate. It sells 22 grades of MCC under the Accel, Acrocell, Maccel and Vincel names to makers of medicines, supplements, food, cosmetics and industrial goods.
It has two plants in Gujarat: Unit I at Pirana, Ahmedabad, with capacity of 2,000 tonnes a year, and Unit II in the Dahej SEZ, Bharuch, with 7,200 tonnes. Exports brought in 63.3% of FY26 revenue, sold in more than 75 countries, partly through distributors. The main raw material is wood pulp, much of it imported.
Read more about the business
To meet orders beyond what its plants can make, the company buys MCC from others, finishes some of it and resells it; it said 25% to 30% of FY26 volume was traded. Premium grades such as silicified MCC and MCC spheres rose to 13.1% of revenue in FY26 from 3.7% a year earlier.
What is new: a third plant, Unit III at Nayka in Kheda district, planned at 2,800 tonnes a year for croscarmellose sodium, carboxymethyl cellulose (CMC) and sodium starch glycolate, with trial runs under way at the time of the FY26 annual report. The company says it will make CMC from wood pulp, which it calls a first in India. The company filed its financial results for the period ended 30 September 2026 with the exchange on 14 October 2026; that filing's text is not among the documents read, so its figures and any update on Unit III are not shown here.
From the offer document, the FY26 annual report, the May 2026 earnings call, the March 2026 CARE rating note and the subject line of the results filing of 14 October 2026.
Read the deeper study ↓In its favour
- Sales have grown fast: 21% a year over three years.
- It earns a high return on the money it uses: ROCE 25% in FY26.
- It has little debt for its size: debt to equity 0.00.
- It paid a dividend in the past year.
To watch
- Commercial start of Unit III Phase 1 at Nayka, Kheda, which the company expected by end June 2026; trial runs were under way at the time of the annual report (Earnings call, May 2026, p.11; Annual report FY26, p.39).
- Phase 2 of Unit III, for MCC: the company gave March 2027 in one answer and the first half of FY28 in another (Earnings call, May 2026, p.10 to 11).
- Traded volumes, which the company says will fall substantially once Phase 2 runs (Earnings call, May 2026, p.9 and p.14).
- Payments from customers: the company said in May 2026 that it is working to cut working capital days (Earnings call, May 2026, p.17).
- Customers take longer to pay than before: 95 days in FY26, against 70 in FY19.
From the company's documents first, then the reported figures read by fixed rules, the same for every company. Facts, not a view on the shares.
Accent Microcell revenue and profit growth
Half-yearly results · Profit and lossSales have grown fast. Last year profit grew roughly in step with sales.
SME companies report every six months. In the latest half, sales were higher than in the same half a year before.
Accent Microcell half-yearly results
SME companies report every six months · ₹ crore
| H1FY24 | H2FY24 | H1FY25 | H2FY25 | H1FY26 | H2FY26 | |
|---|---|---|---|---|---|---|
| Sales | 107 | 139 | 126 | 138.54 | 139.37 | 209.67 |
| Expenses | 87 | 119 | 107 | 115.36 | 115.46 | 176.88 |
| Operating profit | 20 | 20 | 19 | 23.18 | 23.90 | 32.79 |
| OPM | 18.0% | 14.0% | 15.0% | 16.7% | 17.1% | 15.6% |
| Interest | 1 | 0 | 0 | 0.19 | 0.37 | 0.17 |
| Depreciation | 2 | 2 | 2 | 2.17 | 2.07 | 2.58 |
| Profit before tax | 17 | 19 | 20 | 24.26 | 24.06 | 34.20 |
| Net profit | 14 | 16 | 16 | 16.60 | 18.07 | 25.79 |
Accent Microcell profit and loss
Full years to March, FY19 to FY26 · ₹ crore, consolidated where reported
| FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 114 | 131 | 133 | 166 | 197 | 246 | 264.58 | 349.03 |
| Expenses | 108 | 122 | 122 | 153 | 178 | 206 | 222.67 | 292.34 |
| Operating profit | 6 | 9 | 11 | 13 | 19 | 39 | 41.91 | 56.69 |
| OPM | 4.9% | 7.0% | 8.0% | 8.0% | 10.0% | 16.0% | 15.8% | 16.2% |
| Other income | 6 | 4 | 2 | 2 | 2 | 3 | 6.41 | 6.77 |
| Interest | 3 | 3 | 3 | 3 | 3 | 1 | 0.35 | 0.54 |
| Depreciation | 3 | 3 | 4 | 4 | 4 | 4 | 4.21 | 4.66 |
| Exceptional and other items | -1 | -1 | · | · | 1 | · | · | · |
| Profit before tax | 5 | 6 | 6 | 8 | 15 | 37 | 43.76 | 58.26 |
| Tax rate | 20.0% | 33.3% | 16.7% | 25.0% | 20.0% | 18.9% | 24.5% | 24.7% |
| Net profit | 4 | 4 | 5 | 6 | 12 | 30 | 33.06 | 43.86 |
| EPS ₹ | 7.39 | 8.53 | 9.80 | 4.01 | 8.26 | 12.57 | 15.71 | 18.65 |
| Dividend payout | 0.0% | 0.0% | 9.0% | 18.0% | 8.0% | 7.0% | 6.0% | 5.0% |
The years to FY24 come rounded to the nearest crore in the source.
Exceptional and other items: profit before tax beyond operating profit, other income, interest and depreciation, such as one-off items or a share of associates' profit, as reported.
Accent Microcell profitability
Margins and returns on capitalLast year the company kept about as much from each rupee of sales as the year before. It earns a high return on the money it uses.
Operating margin, every year
Per cent of sales kept before interest, depreciation and tax
| FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|
| Operating margin | 4.9% | 7.0% | 8.0% | 8.0% | 10.0% | 16.0% | 15.8% | 16.2% |
| Tax rate | 20.0% | 33.3% | 16.7% | 25.0% | 20.0% | 18.9% | 24.5% | 24.7% |
| ROCE | · | 16.7% | 16.1% | 19.5% | 27.9% | 30.4% | 23.6% | 24.9% |
| ROE | · | 17.4% | 19.6% | 20.7% | 29.3% | 28.0% | 18.4% | 18.7% |
| Dividend payout | 0.0% | 0.0% | 9.0% | 18.0% | 8.0% | 7.0% | 6.0% | 5.0% |
Accent Microcell debt and cash flow
Balance sheet · Cash flow · Working capitalThe company's own money, its net worth, has grown fast. It has almost no borrowings. Last year the business brought in less cash than it showed as profit, so part of the profit is still to be collected. It spent more on assets and investments than the business brought in, and raised the rest from loans or shares. Customers take about as long to pay as they did in FY24.
Bars below the line are cash going out.
Accent Microcell balance sheet
At each 31 March · ₹ crore
| FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 4 | 4 | 4 | 13 | 13 | 21 | 21.04 | 23.99 |
| Reserves | 17 | 21 | 22 | 19 | 37 | 143 | 173.75 | 251.50 |
| Net worth | 21 | 25 | 26 | 32 | 50 | 164 | 194.79 | 275.48 |
| Borrowings | 32 | 30 | 31 | 24 | 23 | 13 | 1.51 | 0.88 |
| Other liabilities | 20 | 22 | 24 | 39 | 38 | 28 | 32.07 | 45.35 |
| Total liabilities | 73 | 77 | 81 | 95 | 111 | 205 | 228.37 | 321.71 |
| Fixed assets | 30 | 29 | 30 | 30 | 31 | 29 | 47.99 | 53.01 |
| Capital work in progress | 0 | 0 | 0 | 0 | 0 | 2 | 13 | 102 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 43 | 48 | 51 | 65 | 80 | 174 | 167.38 | 166.70 |
| Receivables | · | · | · | · | · | · | 64.88 | 91.30 |
| Inventory | · | · | · | · | · | · | 33.63 | 32.41 |
| Cash | · | · | · | · | · | · | 51.02 | 20.10 |
| Trade payables | · | · | · | · | · | · | 18.48 | 19.71 |
Accent Microcell cash flow
₹ crore
| FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 6 | 5 | 5 | 15 | 8 | 11 | 24.67 | 18.64 |
| Cash from investing | -4 | -2 | -6 | -4 | -4 | -82 | -8.61 | -48.88 |
| Cash from financing | -1 | -2 | -2 | -10 | -4 | 72 | -13.70 | 35.75 |
| Net cash flow | 1 | 1 | -3 | 1 | 0 | 1 | 2.36 | 5.51 |
| Capital spending | · | · | · | · | · | · | 36.83 | 87.65 |
Working capital
Days
| FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|
| Debtor days | 70 | 60 | 35 | 38 | 56 | 80 | 90 | 95 |
| Inventory days | 67 | 78 | 128 | 128 | 128 | 83 | 76 | 55 |
| Days payable | 89 | 80 | 74 | 97 | 106 | 48 | 42 | 33 |
| Cash conversion cycle | 48 | 58 | 88 | 68 | 79 | 114 | 124 | 117 |
| Working capital days | 19 | 30 | 37 | 16 | 41 | 79 | 101 | 95 |
Accent Microcell peers and competitors
Listed SME companies in the same industryBy sales, Accent Microcell is number 2 of the 34 listed SME companies in pharmaceuticals & biotechnology.
Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.
| Company | Market cap ₹ cr | P/E | Sales ₹ cr | Profit ₹ cr | Op. margin | Debt/equity |
|---|---|---|---|---|---|---|
| Accent Microcell | 1,466 | 33.4 | 349 | 43.9 | 16.2% | 0.00 |
| Sat Kartar Life | 220 | 12.9 | 201 | 17 | 12.0% | 0.03 |
| Infinium Pharmachem | 471 | 38.7 | 190 | 12.2 | 11.4% | 0.19 |
| Zenith Drugs | 68 | 17.2 | 171 | 3.9 | 7.1% | 0.75 |
| Mono Pharmacare | 16 | 44.6 | 166 | 0.4 | 2.4% | 1.79 |
| Astonea Labs | 341 | 68.1 | 148 | 5 | 9.0% | 0.74 |
| Influx Healthtech | 632 | 30.8 | 147 | 20.5 | 20.3% | 0.00 |
| Jfl Life Sciences | 35 | 5.5 | 131 | 6.4 | 8.9% | 0.47 |
| Dipna Pharmachem | 11 | 3.5 | 129 | 3 | 3.9% | 0.21 |
| Trident Lifeline | 481 | 25.3 | 129 | 19 | 22.0% | 0.73 |
| Chandra Bhagat Pharma | 32 | 10.5 | 116 | 3 | 3.3% | 0.50 |
| Median of the 10 others | 144 | 21.3 | 147 | 5.7 | 8.9% | 0.48 |
Accent Microcell shareholding pattern
Promoters, FIIs, DIIs, HNIs and small holdersThe promoters own more than half the company, a little less than in the first filing shown. Big foreign and Indian funds own very little. The number of shareholders is about the same.
Accent Microcell shareholding pattern
Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.
| Sep 24 | Mar 25 | Jun 25 | Jul 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | |
|---|---|---|---|---|---|---|---|---|
| Promoters | 55.09% | 55.09% | 55.09% | 55.47% | 55.44% | 55.44% | 55.47% | 53.02% |
| Foreign investors (FIIs) | 0.02% | 0.01% | 0.01% | 0.01% | - | 0.29% | 0.58% | 0.91% |
| Indian institutions (DIIs) | 1.66% | 2.19% | 2.88% | 2.90% | 3.29% | 3.57% | 3.59% | 3.54% |
| HNIs (over ₹2 lakh each) | - | 21.21% | 19.21% | 19.36% | 19.73% | 19.29% | 19.71% | 20.22% |
| Small holders (up to ₹2 lakh) | - | 16.28% | 17.11% | 16.40% | 15.77% | 15.35% | 14.54% | 14.63% |
| Companies and others | - | 5.22% | 5.70% | 5.86% | 5.77% | 6.06% | 6.11% | 7.68% |
| Number of shareholders | 2,999 | 2,834 | 2,982 | 3,066 | 3,061 | 3,076 | 3,054 | 3,178 |
The named holders are at 30 June 2026, beside 31 March 2026, each under the group the pattern files them in.
Accent Microcell study: the business from its own documents
Read from 8 of the company's own documentsAccent Microcell so far
From the company's own record
- 15 Dec 2023Listed on NSE Emerge
- 30 June 2026Promoters at 53.02%
- 11 Sept 2026Highest close since listing, ₹725.75
Accent Microcell key facts from the filings
Each figure with the document it comes from
- FY26 revenue
- ₹349.0 cr
- Revenue from operations in FY26, up 31.9% on FY25, with profit after tax of ₹43.9 cr.Annual report FY26, p.3 and p.39
- Plants running full
- 100% and 95%
- Use of capacity in FY26 at the Pirana plant (2,000 tonnes a year) and the Dahej SEZ plant (7,200 tonnes a year).Annual report FY26, p.39 to 40
- Exports
- 63.3% of revenue
- Export revenue of ₹220.9 cr in FY26, the highest in the company's history, sold in more than 75 countries.Annual report FY26, p.39 to 40
- Premium grades
- 3.7% → 13.1%
- Share of revenue from premium products such as silicified MCC and MCC spheres, FY25 to FY26.Annual report FY26, p.39 to 40
- Traded volume
- 25% to 30%
- Share of FY26 volume bought from others and resold to keep customers supplied; the company put the margin on this trade at 4% to 5%.Earnings call, May 2026, p.7 and p.14
Show 5 more facts
- Orders in hand
- About 4,000 tonnes
- Orders from India and abroad that the company said it held at the May 2026 call.Earnings call, May 2026, p.6
- New plant, Unit III
- 2,800 tonnes a year
- Planned capacity at Nayka, Kheda, for croscarmellose sodium, CMC and sodium starch glycolate; paid for from the IPO money, with trial runs under way.Annual report FY26, p.39 to 40; Credit rating note, CARE, March 2026, p.3
- Unit III start date
- Oct 2025 → end June 2026
- First planned for October 2025, moved to April 2026 after slow approvals and two heavy monsoons, then to end June 2026 in the May 2026 call.Credit rating note, CARE, March 2026, p.3; Earnings call, May 2026, p.6 and p.11; Annual report FY26, p.40
- Top ten customers
- 44.1%
- Share of FY25 total operating income from the ten largest customers, up from 39% in FY24.Credit rating note, CARE, March 2026, p.3
- Credit rating
- CARE A-/Stable
- CARE upgraded the long term bank loan rating from BBB+ in March 2026; a CRISIL rating stayed in the issuer not cooperating category in February 2026.Credit rating note, CARE, March 2026, p.2 and p.4
What the company said, and what happened
The company's own statements, attributed, set against what it later reported; not newboard's estimates
In the May 2026 call the company said it held about 4,000 tonnes of orders, that Phase 1 of Unit III, for premium excipients, should start commercial production by end June 2026, and that Phase 2, for MCC, was expected around March 2027, with the first half of FY28 also mentioned. The company said Phase 1 could bring revenue of about ₹150 cr a year at peak capacity, and that traded volumes should fall once Phase 2 runs. The July 2026 annual report said trial runs at Unit III were under way.
| What management said | When | What happened |
|---|---|---|
| Unit III to start commercial operations in October 2025 | Earlier plan, as noted by CARE in March 2026 | Moved to April 2026, then to end June 2026; trial runs under way in the July 2026 annual report |
| Unit III Phase 2 in the second half of FY27 | Earlier plan, as restated in the May 2026 call | Moved to the first half of FY28 in the May 2026 call |
Is it a good business? Six questions
Each answer is about that one question, read from the documents; tap one for the evidence. Not a view on the shares.
Accent Microcell earns its money making plant based powders that hold tablets together, sold mostly abroad to makers of medicines and supplements, and its own plants run almost full.
Its weak spots are a new plant that keeps slipping, a large share of thin margin traded goods, and customers taking longer to pay.
AverageCan it set its own prices?The company says it passes higher wood pulp costs on to customers, and its newer premium grades fetch better prices. The credit rater still counts raw material and currency swings as a risk to margins.
AverageHow strong is it against rivals?Many makers, large and small, offer MCC, but the company holds the certificates drug makers ask for and says few rivals can make MCC spheres.
AverageWho are its customers?Sales are spread across many buyers in many countries, and the ten largest bring in less than half.
AverageDoes it need a lot of money?Borrowing is close to nil and the new plant is paid for with money from share issues, but more cash is now tied up in unpaid customer bills.
StrongCan it keep finding new work?Demand runs ahead of its own output: both plants ran close to full and the company bought in extra product to fill orders.
AverageDo good and bad years swing a lot?Sales have risen steadily, but profit depends on wood pulp prices, the rupee and how much of the volume is traded at thin margins.
Who runs Accent Microcell?
Promoters, directors and officers; tap a name for the background
GAGhanshyam Arjanbhai PatelPromoter, Managing Director and Chief Financial Officer · holds 10.15%
A founder promoter with over 21 years of experience in marketing across agro products, rice processing and excipient manufacturing. Leads strategic planning, administration, finance, HRD and banking at Accent Microcell. The board re-appointed Ghanshyam Arjanbhai Patel as Managing Director for three years from 12 May 2026, subject to shareholder approval.
Annual report FY26, p.30 and p.59 to 61; Offer document, p.162VVVasant Vadilal PatelPromoter and Executive Chairman · holds 9.26%
A founder promoter with over 21 years in the dyes, intermediates, pharmaceutical and nutraceutical industries. Oversees offshore marketing, product development and policy matters. Before Accent, worked at Pooja Fine Chem, a trading company dealing in industrial, pharmaceutical and laboratory chemicals. Re-appointed as Executive Chairman and Whole Time Director for three years from 12 May 2026, subject to shareholder approval.
Annual report FY26, p.30 and p.58 to 59; Offer document, p.162NJNitin Jasvantbhai PatelPromoter and Whole Time Director · holds 15.71%
A founder promoter with over 21 years of experience as a technical director. Responsible for plant projects from planning to completion, production and quality targets, and leads the R&D function; handles the company's new greenfield projects and new products. Spoke for the company on Unit III approvals in the May 2026 call.
Annual report FY26, p.30 and p.61 to 62; Offer document, p.162; Earnings call, May 2026, p.7VMVinodbhai Manibhai PatelPromoter and Whole Time Director · holds 15.46%
Holds a Bachelor of Arts and has over 20 years of experience. Built and runs the company's first plant at Pirana, starting at shop floor level, and leads the company's CSR work and industrial relations.
Annual report FY26, p.30; Offer document, p.162RDRajatkumar Dineshkumar PatelIndependent Director
Holds a Bachelor of Computer Applications and has over seven years of experience in accounts and finance. Also an independent director of Globe Textiles (India) Limited. On the board since May 2023.
Annual report FY26, p.31; Offer document, p.162 and p.166SMShreyaben Milankumar ShahIndependent Director
A qualified Company Secretary and law graduate with about seven years of experience in corporate law and secretarial work; Assistant Company Secretary at PSP Projects. On the board since August 2023. A third independent director, Chintan Umeshkumar Bhatt, resigned on 29 June 2026, citing lack of time.
Annual report FY26, p.31; Offer document, p.166; Exchange announcement, 30 June 2026, p.1Accent Microcell latest news and announcements
Announcements · Documents · Corporate actionsWhat changed recently
Each half-year is set against the same half a year earlier
- H2 FY26: sales ₹210 cr (+51%), net profit ₹25.8 cr (+55%) on H2 FY25.
- Shareholding, 30 June 2026: promoters 55.47% to 53.02%.
Accent Microcell announcements
94 on record, latest first; each opens the filing on the exchange
- Outcome of Board Meeting, the financial results for the period ended September 30, 2026PDF ↗
- Outcome of Board Meeting, the financial results for the period ended September 30, 2026PDF ↗
- Quarterly Compliance Report on Corporate governance - within 21 days from the enAccent Microcell Limited has informed regarding Submission of the Compliance Report on Corporate Governance for the Q_ FY 20__-__PDF ↗
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Certificate under SEBI (Depositories and Participants) Regulations, 2018PDF ↗
- Trading WindowClosure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015PDF ↗
- General UpdatesGeneral UpdatesPDF ↗
- Shareholders meetingSrutinizers report of Annual General Meeting held on July 31, 2026. Further, the company has informed the Exchange regarding voting resultsPDF ↗
- Shareholders meetingwith copy of minutes of Annual General Meeting held on July 31, 2026PDF ↗
- Shareholders meetingProceedings of Annual General Meeting held on July 31, 2026PDF ↗
- Copy of Newspaper PublicationCopy of Newspaper PublicationPDF ↗
- Updates'Intimation of Book Closure 'PDF ↗
- General UpdatesGeneral UpdatesPDF ↗
Accent Microcell annual reports, earnings calls and documents
Every document links to its source; “read” marks those this page is built from
- Offer document ↗read
- 31 May 2026 ↗read
- 31 Aug 2025 ↗read
- 31 May 2025 ↗read
Accent Microcell share split, bonus and dividends
From the corporate actions the company announces on the exchange
- DividendDIVIDEND - RE 1 PER SHAREex-date 17 July 2026
- DividendDIVIDEND - RE 1 PER SHAREex-date 16 Sept 2025
- Rights issueRIGHTS 7:50 @ PREMIUM RS 125/-ex-date 4 June 2025
- DividendANNUAL GENERAL MEETING/DIVIDEND - RE 1 PER SHAREex-date 2 Sept 2024
Checks we ran on Accent Microcell's data · 9
Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.
- ✓Balance sheet totals add up for FY25 and FY26.
- ✓Market cap uses the share count in the latest shareholding pattern (2,39,89,020 shares).
- ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
- ✓Promoter pledge figures are within possible limits in every shareholding pattern shown.
- ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
- ✓The two half-years of FY26 add up to the full-year sales.
- !Earnings per share changes basis between FY21 (₹9.80) and FY22 (₹4.01) because the share count behind it changes; EPS is shown as reported, and growth is worked out on profit.
- ✓Revenue and profit are reported for every year shown, FY19 to FY26.
- iPrices run to the close on 14 Oct 2026, from the exchange's daily figures.
Questions people ask about Accent Microcell
What does Accent Microcell do?
Accent Microcell makes plant based powders from wood pulp that drug, supplement and food makers use to bind and fill tablets and other products. Most of what it makes goes abroad, and its shares trade on NSE Emerge.
What is the share price of Accent Microcell?
₹611 at the close on 6 Nov 2026, from the exchange's daily figures.
What is the market cap of Accent Microcell?
₹1,466 cr at the close on 6 Nov 2026, on 2,39,89,020 shares.
What is the P/E of Accent Microcell?
33.4 times FY26 profit at the close on 6 Nov 2026 (our arithmetic).
What are Accent Microcell's revenue and profit?
Revenue ₹349 cr and profit after tax ₹44 cr in FY26.
Who are the promoters of Accent Microcell?
Ghanshyam Arjanbhai Patel, Vasant Vadilal Patel, Nitin Jasvantbhai Patel, Vinodbhai Manibhai Patel; promoters held 53.02% at 30 June 2026.
What is Accent Microcell's website?
www.accentmicrocell.com
More SME companies like Accent Microcell
Other listed SME companies in pharmaceuticals & biotechnology, the closest in size first, each read from its own documents.
- Remus PharmaceuticalsREMUS · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2023Market cap ₹943 cr
- Aptus PharmaAPPL · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹798 cr
- Influx HealthtechINFLUX · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2025Market cap ₹581 cr
- Trident LifelineTLL · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹495 cr
- KRM AyurvedaKRMAYURVED · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2026Market cap ₹485 cr
- Infinium PharmachemINFINIUM · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2023Market cap ₹435 cr
Every listed SME company in Pharmaceuticals & Biotechnology → · SME companies listed in 2023 →
Built from 3 earnings call transcripts, 2 annual reports, 2 credit rating notes, 1 offer document, 94 exchange announcements, 8 shareholding patterns and 8 years of reported results. Every figure carries its source; where the documents are silent, the page says so.